UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
    February 15, 2024

BELLEVUE LIFE SCIENCES ACQUISITION CORP.
(Exact Name of Registrant as Specified in Charter)

Delaware
  
001-41390
  
84-5052822
(State or Other Jurisdiction
  
(Commission
  
(IRS Employer
of Incorporation)
  
File Number)
 
  
Identification No.)
10900 NE 4th Street, Suite 2300, Bellevue, WA
  
98004
(Address of Principal Executive Offices)
  
(Zip Code)

Registrant’s telephone number, including area code
(425) 635-7700

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading
Symbol(s)
Name of each exchange on
which registered
Units, each consisting of one share of common stock, one redeemable warrant and one right
BLACU
The Nasdaq Stock Market LLC
Common stock, par value $0.0001 per share
 BLAC
The Nasdaq Stock Market LLC
Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share
BLACW
The Nasdaq Stock Market LLC
Right to receive one-tenth (1/10) of one share of common stock
BLACR
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On February 15, 2024, Bellevue Life Sciences Acquisition Corp. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company no longer meets the minimum 300 public holders requirement for The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(3) (the “Minimum Public Holders Requirement”). In accordance with Nasdaq rules, the Company has 45 calendar days, or until April 1, 2024, to submit a plan to regain compliance with the Minimum Public Holders Requirement. If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from the date of the Notice. The Notice has no immediate effect on the listing of the Company’s securities listed on The Nasdaq Capital Market.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: February 21, 2024
 
 
 
BELLEVUE LIFE SCIENCES ACQUISITION CORP.
 
       
 
By:
 /s/ Kuk Hyoun Hwang
   
Name:
 Kuk Hyoun Hwang
   
Title:
Chief Executive Officer

v3.24.0.1
Document and Entity Information
Feb. 15, 2024
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 15, 2024
Entity File Number 001-41390
Entity Registrant Name BELLEVUE LIFE SCIENCES ACQUISITION CORP.
Entity Central Index Key 0001840425
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 84-5052822
Entity Address, Address Line One 10900 NE 4th Street
Entity Address, Address Line Two Suite 2300
Entity Address, City or Town Bellevue
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98004
City Area Code 425
Local Phone Number 635-7700
Entity Emerging Growth Company true
Entity Ex Transition Period false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Units, each consisting of one share of common stock, one redeemable warrant and one right [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Units, each consisting of one share of common stock, one redeemable warrant and one right
Trading Symbol BLACU
Security Exchange Name NASDAQ
Common stock, par value $0.0001 per share [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol BLAC
Security Exchange Name NASDAQ
Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share
Trading Symbol BLACW
Security Exchange Name NASDAQ
Right to receive one-tenth (1/10) of one share of common stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Right to receive one-tenth (1/10) of one share of common stock
Trading Symbol BLACR
Security Exchange Name NASDAQ
Bellevue Life Sciences A... (NASDAQ:BLACU)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Bellevue Life Sciences A... Charts.
Bellevue Life Sciences A... (NASDAQ:BLACU)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Bellevue Life Sciences A... Charts.